MeiraGTx Holdings plc Stock News

Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx's Technology Platforms for Gene and Cell Therapy Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx's Technology Platforms for Gene and Cell Therapy

-  Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson's disease -  U.S. Food and Drug Administration (FDA) Granted Regenerative Medicine Advanc...

-  This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease -  RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regulatory interactions with the FDA, and potential routes to accelerated approval and Priority Review LONDON and NEW YOR...

The global cone rod dystrophy market, valued at US$131.29 million in 2024, is projected to reach US$177.59 million by 2030, growing at a CAGR of 5.33%. Key drivers include advancements in gene therapies, personalized medicine, and government programs. North America remains the largest market, while Asia Pacific leads growth. Major players like SparingVision and Beacon Therapeutics propel innova...

MeiraGTx (MGTX) develops gene therapies for ocular diseases, Parkinson's Disease, and xerostomia, with multiple assets in advanced clinical stages showing promising efficacy and safety data. MGTX uses AAV5 capsid vectors and riboswitch technology to deliver gene therapies, aiming for safer and more controlled treatments compared to earlier approaches. Financially, MGTX has a strong cash positio...

-  Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson's disease -  MeiraGTx and Hologen have created the first neuro-AI clinical drug developm...

- MeiraGTx to receive $200 million in upfront cash consideration - MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen to fund 100% of the development of AAV-GAD for Parkinson's disease through to commercialization, as well as other potential pipeline products - MeiraGTx will enter into clinical and commercial supp...

LONDON and NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the publication of results from the first-in-human interventional study to treat children with AIPL1-associated severe retinal dystrophy. The data were published in The Lancet in a paper titled, "Gene therapy in children ...